Program
FXS887
A development code.
Its studies are led by Fosun Pharma.
Furthest: phase 1, since Dec 23, 20251 company-led study, 1 open or runningNext primary completion: Apr 28, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 11 open or running | phase 1since Dec 23, 2025 | Dec 23, 2025 | Apr 28, 2027phase 1 · NCT07345637 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 23, 2025First study: phase 1 study in Solid Tumor Refractory to Conventional TreatmentFirst studyNCT07345637 · 14 planned · China
Ahead
- Apr 28, 2027Primary completion: phase 1 study in Solid Tumor Refractory to Conventional TreatmentNCT07345637
TargetBeta
ATR →read by rule
“FXS887 is a innovative ATR inhibitors of a class of small-molecule inhibitors targeting ATR kinase.”study text, by rule · the study
Other programs on ATR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ceralasertibrule | AstraZeneca | phase 3 | 16 |
| TCC1727 | Sino Biopharmaceutical | phase 2 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07345637Solid Tumor Refractory to Conventional Treatment · China | 1 | Not yet recruiting | Apr 28, 2027 | 14 |
How it is read
Names in the registry
- “FXS887”, 1 entry
Codes read as this program: FXS887.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.